聚万力擎未来|以岭万洲万洋亮相CPHI Frankfurt 2025

创建时间：2025-12-03

CPHI Frankfurt 2025于2025年10月28日至30日在德国法兰克福会展中心隆重举行。作为全球医药行业最具影响力的专业展会之一，本次展会展商数量超过2,400家，吸引来自全球160多个国家和地区的62,000余名制药专业人士到场进行商贸交流。

以岭万洲国际制药总经理、万洋衡水制药董事长杨永涛先生携国际销售团队、CMO团队，深度参与本次全球行业交流大会。

CPHI Frankfurt 2025 held from October 28 to 30,2025,at the Messe Frankfurt in Germany.As one of the most influential exhibitions in global pharmaceutical industry,this event hosted more than 2,400 exhibitors and attracted over 62,000 pharmaceutical professionals from 160 countries and regions worldwide for business and trade exchanges.

Mr. Yang Yongtao,General manager of Yiling Pharmaceutical LTD together with crew,participated in this global conference.

展会现场速递

作为CPHI系列展会的长期参与者与行业发展见证者，以岭万洲国际制药紧扣行业智能化与绿色转型趋势，在展位（Booth：4.1A42）重磅亮相，全面展示在API与CMO领域的高质量服务能力与创新解决方案。展会期间，万洲展区吸引众多海内外客户驻足交流。团队凭借专业细致的讲解，系统呈现了从药物研发到商业化生产的全流程高效支持体系，赢得了国际客户的广泛认可与赞誉，为深化全球合作奠定了坚实基础。

万洲国际制药立足全球视野，历经多年深耕发展，公司已成功构建起辐射全球的供应链网络与高效协同的运营体系。我们以领先的研发实力、对标国际的质量管理体系与稳定可靠的交付能力为根基，持续为全球医药健康领域输出高品质产品与专业化解决方案。在持续积累核心技术能力与规模优势的过程中，公司不断将硬实力转化为深度的品牌认同与长期战略价值，已成为众多国际知名药企高度信赖的合作伙伴。

面向未来，万洲万洋将始终秉持“以客户为中心”的核心理念，全面增强自主创新能力，系统布局前沿技术平台，持续优化全球产能配置，精准响应并引领客户日益升级的多元需求。我们致力于成为全球医药产业生态中重要的创新引擎与价值伙伴，以持续突破助力客户实现战略跃迁，携手各界伙伴，共同开创医药健康事业的高质量新未来。

As a long-term participant and witness to the development of the CPHI exhibition series, Yiling Pharmaceutical Ltd.closely aligned with industry trends in intelligent and green transformation,making a standout appearance at its exclusive booth (Booth: 4.1A42).The booth comprehensively showcased its high-quality service capabilities and innovative solutions in the fields of APIs and Contract Manufacturing Organization (CMO). During the event，the booth attracted a steady flow of domestic and international clients.Through professional and detailed presentations,the team systematically demonstrated its end-to-end efficient support system from drug development to commercial production, earning widespread recognition and high praise from global clients and laying a solid foundation for deeper international collaboration.

After years of steady and in-depth development,the company has established a globally reaching supply chain network and an efficient, collaborative operational system.With leading R&D capabilities, internationally benchmarked quality management systems,and reliable delivery capacity as our foundation,we continue to provide high quality products and professional solutions to the global healthcare sector.By continuously strengthening our core technological competencies and scaling advantages,we are translating these strengths into deeper brand trust and long-term strategic value,earning the confidence of numerous internationally renowned pharmaceutical companies as a trusted partner.

Looking ahead,Yiling Pharmaceutical Ltd.will remain committed to our customer-centric philosophy,comprehensively enhancing independent innovation capabilities,systematically building cutting-edge technology platforms, and continuously optimizing global production capacity allocation.We strive to accurately anticipate and meet the evolving diverse needs of our clients.Our goal is to become a key innovation engine and value partner within the global pharmaceutical ecosystem.Through persistent breakthroughs,we will support our customers in achieving strategic leaps forward,working hand-in-hand with partners across the industry to usher in a new phase of high-quality growth in global healthcare.

以岭万洲国际制药有限公司

以岭万洲国际制药有限公司是以岭集团的全资子公司，承担了集团化学制药板块的发展重任。

以岭万洲建立了一支国际化的研发、质量、生产、营销团队，高层管理者均拥有长期跨国制药公司任职背景和卓越的专业经验。万洲是中国向欧美出口制剂最多的企业之一，多次通过美国、英国、澳大利亚、加拿大、新西兰等国的GMP认证，是国内少数同时通过欧美GMP认证的企业之一。

As a wholly-owned subsidiary of Yiling Group,Yiling Pharmaceutical Ltd.is solely responsible for the innovative development of chemical drugs.

Yiling Pharma is managed by strong team of R&D,Production,Quality,Marketing & Sales.Management team possess multinational pharma corporation background and excellent expertise.Yiling ranks in one of the largest China's enterprises exporting ﬁnished drugs to regulated market.Facilities have been certiﬁed by US FDA,MHRA,China NMPA,TGA,Health Canada and Medsafe for many times.

制剂及原料药生产基地

以岭万洲共有三个生产基地，涵盖原料药、制剂生产。建立了抗肿瘤药物、缓控释制剂、注射剂研发和转移平台，累计已持有14个美国产品批文，且已经承接多个代加工项目，并完成或正在进行100+技术转移。当前制剂生产场地综合生产能力达到72亿片/粒, 另有预留产能200亿片；1亿支生产能力的注射剂车间已建设完成并投入使用。

Yiling Pharma owns three manufacturing sites for API and Formulation products.Yiling’s technical team drives projects from pre-formulation development to commercial scale manufacture,and have owned 14 ANDAs in US market,and undertaken multiple CMO projects,at the same time have ﬁnished or been running 100+ technology transfers projects.The annual capacity of Formulation sites exceeds 72 billion units,there is a reserved capacity of 20 billion units,and an injection workshop with a production capacity of 100 million units has been completed and put into use.